A flurry of dividend cuts across the FTSE 100 has caused investors to become increasingly sceptical over the payout forecasts for many of Britain’s leading blue-chips.
Medicines giant GlaxoSmithKline (LSE: GSK) and oil mammoth BP (LSE: BP) are two such stocks that have come under rising scrutiny from income chasers. But are these concerns truly merited?
If you want to find out, continue reading...
Source: The Motley Fool
